Who Does What: NAFDAC Directorates and the FDRC Approval Meeting

1. Key takeaways

Device regulation in Nigeria is not handled by a single department. It is a division-of-labor structure of four technical directorates plus one approval meeting:

There is also a pharmacovigilance channel: Manufacturer Investigation Reports (MIRs) and adverse events for devices and IVDs are submitted to the designated pharmacovigilance mailbox in accordance with the guidance on the official NAFDAC pages.

Read as a whole, this division of labor also explains why complaints about slow review often have a different root cause: an application may be sitting at the laboratory, or waiting for GMP inspection scheduling, while the applicant keeps following up with the wrong directorate. Mapping each stage to its responsible unit before filing avoids that loss of time.

2. Legal basis

3. Expert insights

Insight 1: imported and locally manufactured devices have different sampling authorities, and this step decides how samples get to the laboratory.

Guideline §8.1 provides that for imported devices, the applicant delivers the registration samples to the VBM-R&RA Directorate after import, for onward transmission to laboratory analysis. Section 8.2 provides that locally manufactured devices are sampled by the DER Directorate. A local manufacturing project therefore cannot deliver its own samples; it must cooperate with DER’s sampling arrangements.

Insight 2: the official guidance for GMP inspection hangs under the DER Directorate.

The 2024 guideline, §5.1, expressly requires applicants to consult the DER Directorate section of the NAFDAC website for information on inspection of manufacturing facilities (applicable to imported and locally manufactured devices). This explains why the device GMP guideline carries the number DER-GDL-025-00 (effective 11 November 2024) — the file sits with DER, not with VBM-R&RA.

Insight 3: there is an official timeline for laboratory analysis, but it primarily addresses vaccines and biologics.

The NAFDAC website states that the analysis timeline of the Vaccines, Biologics and Medical Devices Laboratory Services Directorate is 60 working days, and lists situations in which samples may be rejected (cold-chain interruption, insufficient sample quantity, missing documents, unclear labelling, mismatch between product information and documents, and remaining shelf life of less than 6 months). This 60-working-day figure comes from the laboratory services directorate page; the registration guideline itself does not repeat it, and the source level should be noted when citing.

Insight 4: the FDRC approval meeting is a decision point, not a formality.

Both registration guidelines state that after satisfactory completion of document review, GMP inspection of the manufacturing facility and laboratory analysis (where applicable), the product is submitted to the FDRC approval meeting; products approved at the meeting receive an electronic product registration certificate issued to the applicant. This means that if any of the first three stages is unsatisfactory, the product never reaches the meeting.

Insight 5: post-market surveillance and recalls have an independent guideline system, numbered under PMS.

The PMS Directorate issued two guidelines in September 2024: PMS-GDL-016-01 (post-market surveillance, effective 27 September) and PMS-GDL-020-00 (recall of defective medical products, effective 30 September). When building a post-market system, companies should benchmark directly against these two guidelines, not merely cite the principles of regulation 12 of the Regulations.

4. Practical recommendations

1. Build the contact map directorate by directorate: VBM-R&RA (receipt and dossier), DER (GMP and local sampling), Laboratory (analysis), PMS (post-market).
2. Engage DER early on sampling arrangements for local manufacturing projects; do not deliver samples under the import logic.
3. Prepare GMP compliance against DER-GDL-025-00, and prepare invitation letters and related materials for foreign factory inspections in parallel.
4. Watch the laboratory rejection conditions in sample management, especially the remaining shelf life of less than 6 months rule.
5. Benchmark the post-market system directly against PMS-GDL-016-01 and PMS-GDL-020-00.

5. Verification checklist

• □ Responsible directorates confirmed for the project: VBM-R&RA / DER / Laboratory / PMS.
• □ Import projects prepared sample delivery under §8.1; local manufacturing projects confirmed sampling arrangements with DER.
• □ GMP preparation benchmarked against DER-GDL-025-00 (2024-11-11).
• □ Samples checked against laboratory rejection conditions (cold chain, quantity, documents, labelling, shelf life 6 months).
• □ Confirmed the FDRC approval meeting as the final decision stage.
• □ Post-market system benchmarked against PMS-GDL-016-01 (2024-09-27) and PMS-GDL-020-00 (2024-09-30).

Regulatory information verified as of 29 October 2026. The content cited was checked against the registration guidelines published on the NAFDAC website (VBM-R&RA-GDL-001-01 §3.1–§3.2, §8.0–§9.0; R&R-GDL-008-02 §5.0–§8.0), the organizational structure pages and the laboratory services directorate page. Updates are re-checked whenever the regulations or pages change.

GRZAN support for the Nigerian market. GRZAN provides NAFDAC registration and compliance support for the Nigerian market, with local resources covering coordination with licensed importers and authorized representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Service capabilities cover classification assessment, registration pathway selection, technical documentation to the IMDRF ToC, CMFS and legalization support, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, variation management and certificate renewal. Contact: info@grzanglobal.com.